0001104659-21-143142.txt : 20211123
0001104659-21-143142.hdr.sgml : 20211123
20211123184135
ACCESSION NUMBER: 0001104659-21-143142
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211119
FILED AS OF DATE: 20211123
DATE AS OF CHANGE: 20211123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Malin Life Sciences Holdings Ltd
CENTRAL INDEX KEY: 0001685138
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39376
FILM NUMBER: 211440525
BUSINESS ADDRESS:
STREET 1: 2 HARBOUR SQUARE
STREET 2: CROFTON ROAD
CITY: DUN LAOGHAIRE, CO, DUBLIN
STATE: L2
ZIP: ----
BUSINESS PHONE: 353 1 901 5701
MAIL ADDRESS:
STREET 1: 2 HARBOUR SQUARE
STREET 2: CROFTON ROAD
CITY: DUN LAOGHAIRE, CO, DUBLIN
STATE: L2
ZIP: ----
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Poseida Therapeutics, Inc.
CENTRAL INDEX KEY: 0001661460
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 472846548
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9390 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-779-3100
MAIL ADDRESS:
STREET 1: 9390 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
tm2133357-2_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-11-19
0
0001661460
Poseida Therapeutics, Inc.
PSTX
0001685138
Malin Life Sciences Holdings Ltd
THE LENNOX BUILDING
50 RICHMOND STREET SOUTH
DUBLIN, IRELAND
L2
D02 FK02
IRELAND
0
0
1
1
Common director with Issuer
COMMON STOCK
2021-11-19
4
P
0
11104
7.4433
A
9578605
D
COMMON STOCK
2021-11-23
4
P
0
14625
6.7685
A
9593230
D
The reported prices in Column 4 are weighted average prices. Those shares were purchased in multiple transactions at per share prices ranging from $7.37 to $7.54 on 11/19/2021; and $6.695 to $6.89 on 11/23/2021. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
/s/ Pat Jennings, Chief Financial Officer
2021-11-23